Robert J Commons
Overview
Explore the profile of Robert J Commons including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watson J, Mehdipour P, Moss R, Jittamala P, Zaloumis S, Price D, et al.
Antimicrob Agents Chemother
. 2025 Feb;
:e0154924.
PMID: 39992119
Primaquine is the only widely available drug to prevent relapses of malaria. Primaquine is underused because of concerns over oxidant hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency. A pharmacometric trial showed...
2.
Daneman N, Rishu A, Pinto R, Rogers B, Rogers B, Shehabi Y, et al.
N Engl J Med
. 2024 Nov;
392(11):1065-1078.
PMID: 39565030
Background: Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. Methods: In a multicenter, noninferiority trial, we...
3.
Commons R, Rajasekhar M, Allen E, Yilma D, Chotsiri P, Abreha T, et al.
Lancet Child Adolesc Health
. 2024 Sep;
8(11):798-808.
PMID: 39332427
Background: Primaquine, the only widely available treatment to prevent relapsing Plasmodium vivax malaria, is produced as 15 mg tablets, and new paediatric formulations are being developed. To inform the optimal...
4.
Fadilah I, Commons R, Chau N, Chu C, Day N, Koh G, et al.
PLoS Med
. 2024 Sep;
21(9):e1004411.
PMID: 39331646
Background: The 8-aminoquinolines, primaquine and tafenoquine, are the only available drugs for the radical cure of Plasmodium vivax hypnozoites. Previous evidence suggests that there is dose-dependent 8-aminoquinoline induced methaemoglobinaemia and...
5.
Malone M, Bergamin E, Hayashi K, Schwarzer S, Dickson H, Lau N, et al.
J Foot Ankle Res
. 2024 Jul;
17(3):e12040.
PMID: 38982577
Background: Diabetes-related foot infections are common and represent a significant clinical challenge. There are scant data about outcomes from large cohorts. The purpose of this study was to report clinical...
6.
Ahmad S, Verma R, Commons R, Nitika , Singh-Phulgenda S, Chhajed R, et al.
Trials
. 2024 Feb;
25(1):154.
PMID: 38424577
Background: Plasmodium vivax remains a major challenge for malaria control and elimination due to its ability to cause relapsing illness. To prevent relapses the Indian National Center for Vector Borne...
7.
Watson J, Commons R, Tarning J, Simpson J, Llanos Cuentas A, Lacerda M, et al.
Elife
. 2024 Feb;
13.
PMID: 38323801
In our recent paper on the clinical pharmacology of tafenoquine (Watson et al., 2022), we used all available individual patient pharmacometric data from the tafenoquine pre-registration clinical efficacy trials to...
8.
Verma R, Commons R, Gupta A, Rahi M, Nitika , Bharti P, et al.
BMJ Glob Health
. 2023 Dec;
8(12).
PMID: 38123228
Background: The optimal dosing of primaquine to prevent relapsing malaria in South Asia remains unclear. We investigated the efficacy and safety of different primaquine regimens to prevent relapse. Methods: A...
9.
Lazzarini P, Raspovic A, Prentice J, Commons R, Fitridge R, Charles J, et al.
Med J Aust
. 2023 Oct;
219(10):485-495.
PMID: 37872875
Introduction: Diabetes-related foot disease (DFD) - foot ulcers, infection, ischaemia - is a leading cause of hospitalisation, disability, and health care costs in Australia. The previous 2011 Australian guideline for...
10.
Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, et al.
Malar J
. 2023 Oct;
22(1):306.
PMID: 37817240
Background: Imperfect adherence is a major barrier to effective primaquine radical cure of Plasmodium vivax. This study investigated the effect of reduced adherence on the risk of P. vivax recurrence....